Can Molbio Diagnostics IPO deliver long-term growth for high risk investors?
Molbio Diagnostics aims to secure ₹200 crore to enhance its capital expenditures through a new issuance of shares. In tandem, the firm intends to reduce promoter stake by generating ₹740 crore via an offer for sale. With six manufacturing sites worldwide, the company caters to over ninety nations and has seen substantial revenue growth attributed to its tuberculosis diagnostic test kits.
Molbio Diagnostics, a molecular diagnostics manufacturer founded in 2000, is set to raise ₹200 crore through a fresh issue and an additional ₹740 crore through an offer for sale to fund capital expenditure. The company operates six manufacturing facilities across India and serves customers in over 90 countries, with nearly 74% of its revenue coming from the sale of test kits, predominantly for Tuberculosis.
With a strong focus on research, development, and manufacturing of diagnostic solutions for infectious and non-communicable diseases, Molbio's top clients contribute over half of its revenue, indicating a customer concentration risk. The company's Truenat platform, a portable diagnostics system for resource-limited settings, offers accurate test results within an hour, serving a wide range of diseases through 43 diagnostic assays.
Despite the high-risk nature of investing in an IPO at this stage, the company's robust financial performance, with revenue from operations rising 31.5% annually and net profit growing 40.2% annually over the past two fiscal years, suggests potential for long-term growth for high-risk investors.
Brief written by urgent.news from The Economic Times - Top News's own syndicated text. Machine-written — it may contain errors, so check the original before relying on it.
